Longitudinal study of HIV-specific cytotoxic lymphocytes in HIV type 1-infected patients: relative balance between host immune response and the spread of HIV type 1 infection.

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Longitudinal study of HIV-specific cytotoxic lymphocytes in HIV type 1-infected patients: relative balance between host immune response and the spread of HIV type 1 infection.

AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1301-12. Unique Identifier : AIDSLINE MED/97479766
Bariou C; Genetet N; Ruffault A; Michelet C; Cartier F; Genetet B; Groupe Universitaire de Recherche en Immunologie Fondamentale et; Appliquee, Universite de Rennes I, France.

Abstract: To evaluate the contribution of a specific cytotoxic response in the control of HIV infection in relation to clinical status, we performed serial analysis of anti-Env and anti-Gag cytotoxic activity in 13 infected individuals over a 6- to 10-year period, using cryopreserved peripheral blood mononuclear cells (PBMCs). Autologous EBV-transformed B cell lines infected in vitro with recombinant vaccinia viruses expressing HIV-1 env and gag genes were used as targets. Without any stimulation of the effector cells, we were able to show an anti-HIV cytotoxic activity in the PBMCs of 12 of 13 HIV-1-infected patients, consistent with chronic immune activation in HIV infection. Different patterns of HIV-specific cytotoxic activity were observed, and the extent of this cytotoxic response varied between the clinically defined groups of individuals. No direct relationship was observed with the number of CD4 and CD8 lymphocytes during the observation period. However, patients who remained asymptomatic had a more vigorous cytotoxic response than patients with clinical deterioration during the observation period, and a significant difference was observed for HIV Gag-specific CTL activity. From these data, we suggest that the HIV-specific cytotoxic response has a protective role in the course of HIV infection.

Keywords: B-Lymphocytes/IMMUNOLOGY Cryopreservation Cytotoxicity Tests, Immunologic CD4 Lymphocyte Count CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Gene Expression Gene Products, env/GENETICS/IMMUNOLOGY Host-Parasite Relations Human HIV Antigens/*IMMUNOLOGY HIV Core Protein p24/GENETICS/IMMUNOLOGY HIV Infections/DIAGNOSIS/*IMMUNOLOGY HIV-1/*IMMUNOLOGY/*PATHOGENICITY Leukocytes, Mononuclear/IMMUNOLOGY Longitudinal Studies Lymphocyte Count Recombination, Genetic Support, Non-U.S. Gov't Survivors T-Lymphocytes, Cytotoxic/*IMMUNOLOGY Transformation, Genetic Vaccinia Virus/GENETICS Viral Load JOURNAL ARTICLE
980228
M9820723

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .